New Triple-Action antibody takes on Hard-to-Treat cancers
NCT ID NCT07533708
First seen Apr 18, 2026 · Last updated May 15, 2026 · Updated 5 times
Summary
This early-phase study tests a new drug called HLX3902 in about 48 adults with advanced prostate cancer or other solid tumors that have stopped responding to standard treatments. The drug is a special antibody designed to help the immune system attack cancer cells. The main goals are to check the drug's safety, find the best dose, and see how the body processes it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MCRPC OR ADVANCED/METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.